publication date: Jun. 30, 2016

Breast Cancer Combination of Surgery and Standard Therapy Increases Survival in Stage IV, Study Says

 

A combination of surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by standard therapies, can add months to patients’ lives when compared with standard therapy alone, according to an international phase III study.

“Our findings will change the standard of care for women newly diagnosed with stage IV breast cancer,” said lead investigator Atilla Soran, clinical professor of surgery at the University of Pittsburgh School of Medicine and breast surgical oncologist with UPMC CancerCenter. “We’ve shown that surgery to remove the primary tumor—either through lumpectomy or mastectomy—followed by standard therapy, is beneficial over no surgery.”

The trial began in 2007, recruiting 274 women with newly diagnosed stage IV breast cancer from 25 institutions. Half the women received standard therapy, which avoids surgery and consists of a combination of chemotherapy, hormonal therapy and targeted therapy, while the other half first had surgery to remove their primary breast tumor, followed by the standard therapy.

The results were presented at the annual meeting of the American Society of Clinical Oncology, and the study was selected for the “Best of ASCO” two-day program.

At about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine … Continue reading CCL June 2016 – Combination of Surgery and Standard Therapy Increases Survival in Stage IV, Study Says

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.